Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for Triple Receptor-Negative Breast Cancer With Residual Invasive Cancer After Neoadjuvant Chemotherapy.

Trial Profile

Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for Triple Receptor-Negative Breast Cancer With Residual Invasive Cancer After Neoadjuvant Chemotherapy.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Capecitabine
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top